Previous 10 | Next 10 |
Kala Pharmaceuticals press release (NASDAQ:KALA): Q1 GAAP EPS of -$0.45 misses by $0.11. Non-GAAP net loss was $29.5M. Revenue of $1.37M (-58.1% Y/Y) misses by $1.51M. For further details see: Kala Pharmaceuticals GAAP EPS of -$0.45 misses by $0.11, revenue of $1.37M misses by $1.51M
- Expanded Coverage for EYSUVIS® to 92% of Total Commercial Lives and 30% of All Medicare Lives - - Achieved 18% EYSUVIS Prescription Growth in 1Q 2022 - - Presented KPI-012 Phase 1b Clinical Data at ARVO; Initiation of Phase 2/3 Clinical Trial in PCED Expected 4Q 202...
Kala Pharmaceuticals (NASDAQ:KALA) is scheduled to announce Q1 earnings results on Monday, May 16th, before market open. The consensus EPS Estimate is -$0.29 and the consensus Revenue Estimate is $2.88M (-11.9% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward revision and 0 down...
ARLINGTON, Mass., May 09, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will report first qu...
Most people think of penny stocks as shares of companies trading for pennies. The standard definition considers these as stocks under $5, but you can’t argue with popular opinion. The exciting part about penny stocks under $1 is the volatility and gain potential they hold. Ca...
Kala Pharmaceuticals (NASDAQ:KALA) said that a large pharmacy benefit manager in the U.S. added dry eye disease therapy Eysuvis as a covered brand on its commercial formularies, effective May 1. The company said this adds 28.5M commercial lives to Eysuvis (loteprednol etabonate opht...
-- Now Covered by the largest Pharmacy Benefit Manager in the United States and Humana Medicare-- --Expands Commercial coverage to 92% of total commercial lives-- --Doubles Medicare coverage from 7.1 million lives to 14.1 million lives-- ARLINGTON, Mass., May 03, 2022 (G...
-- Data Demonstrate Rapid and Complete Wound Healing, with Six of Eight (75%) Patients Achieving Complete Healing within Four Weeks; All Remained Healed Through End of Follow-Up -- -- All Patients with Pain at Baseline Reported Zero Pain by Week 3 -- -- KPI-012 was Well-Tolera...
ARLINGTON, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that it will present data ...
JP Morgan has downgraded Kala Pharmaceuticals (NASDAQ:KALA) to underweight from neutral as the firm said that sales of the dry eye treatment Eysuvis (loteprednol etabonate) were below expectations. The firm cut its sales expectations in fiscal year 2022 for the eye drops as follows: Q1, $1.9M...
News, Short Squeeze, Breakout and More Instantly...
Kala Pharmaceuticals Inc. Company Name:
KALA Stock Symbol:
NASDAQ Market:
Kala Pharmaceuticals Inc. Website:
2024-07-27 11:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 30.9% to $0.6 on volume of 558,931,853 shares NVIDIA Corporation (NVDA) fell 1.9% to $123.99 on volume of 249,243,816 shares Assure Holdings Corp. (IONM) rose 82.8% to $0.424 on vol...
Kala Pharmaceuticals, Inc. (NASDAQ: KALA) is one of today's top gainers. The company's shares have moved 44.91% on the day to $6.55. Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus pe...